Your Location：Home >Products >Pharmaceutical >51110-01-1
Appearance:powder
Throughput:100|Kilogram|Month
pd_productuse:API
Delivery Time:large stock
Purity:99% purity
Somatostatin Chemical Properties
storage temp. −20°C
solubility H2O: 1 mg/mL
form powder
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
WGK Germany 3
RTECS WF8751700
F 3-10-21
Description Originally isolated from hypothalamic tissue, somatostatin is characterized as an inhibitor of growth hormone (GH) release. The structure was determined in 1971. Subsequent investigations led to the recognition that somatostatin also was released from the pancreas and has a role of inhibiting the secretion of both insulin and glucagon. A total of five somatostatin receptor subtypes have been characterized and cloned (sst1 to sst5). Subtype sst4 is associated with the inhibition of insulin release, and an sst4-selective inhibitor has been reported. The somatostatin analogue SOM230 has exhibited selectivity for sst1, sst2, sst3, and sst5 in rats and effectively decreased plasma GH and insulin-like growth factor-1 (IGF-1) levels by 75% without significant effects on insulin or glucagon. Another analogue, PT R3173, with selectivity for recombinant human somatostatin receptor (hsst2, hsst4, hsst5) was substantially more effective in inhibiting GH secretion compared to glucagon and insulin release in rats.
Uses Somatostatin is a peptide hormone that regulates the endocrine system
CAS：1257044-40-8
CAS：881681-00-1
CAS：78409-50-4
CAS：1193-21-1
